Pancreatic Cancer Research

ResearcherUniversity of Alabama at BirminghamActive in the last 2 years

Upender Manne

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1545-3032; OpenAlex author ID A5038817160; NIH RePORTER profile ID 7008046. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 1)
Trials
0
Grants
1
Labs led
0
Collaborators
60
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 3 papers, 1 grant · 2025: 3 papers · 2026: 3 papers

Papers 12

  1. Inferring Clinically Relevant Molecular Subtypes of Pancreatic Cancer from Routine Histopathology Using Deep Learning Co-author DOI 10.21203/rs.3.rs-8545050/v1↗
  2. Molecular Characterization of Small Extracellular Vesicles in Pancreatic Cancer Patients Treated with Neoadjuvant Chemotherapy Followed by Stereotactic Body Ra… Co-author DOI 10.3390/cancers18111704↗
  3. Inferring Clinically Relevant Molecular Subtypes of Pancreatic Cancer from Routine Histopathology Using Deep Learning Co-author DOI 10.64898/2026.01.06.26343539↗
  4. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Co-author DOI 10.1016/j.xcrm.2024.101881↗
  5. ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-025-02288-9↗
  6. Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. Co-author DOI 10.3389/fonc.2025.1544928↗
  7. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.neo.2023.100951↗
  8. Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy Co-author DOI 10.20944/preprints202409.0945.v1↗
  9. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. Co-author DOI 10.3390/ijms25169041↗
  10. An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer. Co-author DOI 10.1016/j.csbj.2023.11.029↗
  11. PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. Co-author DOI 10.1016/j.tranon.2020.100776↗
  12. Advances in pancreatic cancer biomarkers. Co-author DOI 10.4081/oncol.2019.410↗

Grants 1

  1. Admin-Core-001 U54CA118948↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ashish Manne · 6 shared papers, 2024–2026 · strength 1.35
  2. Ashwini Kumar Esnakula · 5 shared papers, 2024–2026 · strength 1.04
  3. Ravi Kumar Paluri · 5 shared papers, 2019–2026 · strength 0.97
  4. Anne M. Noonan · 4 shared papers, 2024–2026 · strength 0.83
  5. Clayton Yates · 1 shared grant, 2024 · strength 0.72
  6. Brian M. Rivers · 1 shared grant, 2024 · strength 0.72
  7. Muhammad Khalid Khan Niazi · 2 shared papers, 2026 · strength 0.53
  8. Abdul Akbar · 2 shared papers, 2026 · strength 0.53
  9. Susan Tsai · 2 shared papers, 2026 · strength 0.53
  10. Vaibhav Sahai · 2 shared papers, 2026 · strength 0.53
  11. Kannan Thanikachalam · 3 shared papers, 2024–2025 · strength 0.51
  12. Wancai Yang · 3 shared papers, 2024–2025 · strength 0.51
  13. Lianbo Yu · 3 shared papers, 2024–2025 · strength 0.51
  14. Ankur Sheel · 3 shared papers, 2024–2025 · strength 0.51
  15. Jordan M. Cloyd · 3 shared papers, 2024–2025 · strength 0.51
  16. Anup Kasi · 3 shared papers, 2024–2025 · strength 0.51
  17. Julienne L. Carstens · 2 shared papers, 2025 · strength 0.38
  18. Sujith Sarvesh · 2 shared papers, 2025 · strength 0.38
  19. Dhana Sekhar Reddy Bandi · 2 shared papers, 2025 · strength 0.38
  20. Karina Jin Yoon · 2 shared papers, 2025 · strength 0.38
  21. Ganji Purnachandra Nagaraju · 2 shared papers, 2025 · strength 0.38
  22. Jeremy B. Foote · 2 shared papers, 2025 · strength 0.38
  23. Mehmet Akce · 2 shared papers, 2025 · strength 0.38
  24. Bassel F. El‐Rayes · 2 shared papers, 2025 · strength 0.38
  25. Farrukh Afaq · 2 shared papers, 2023–2024 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.